Analyst rating score for ZIOPHARM Oncology, Inc. (ZIOP) stands at 2.50

Adjust Comment Print

IVTJF's SI was 21,900 shares in March as released by FINRA. BMO Capital Markets maintained the shares of Monday in report on Friday, September 1 with "Buy" rating.

ZIOPHARM Oncology, Inc. (ZIOP) formed wedge down with $4.11 target or 3.00% below today's $4.24 share price.

Technical analysis of ZIOPHARM Oncology, Inc. About 220,757 shares traded.

ZIOPHARM Oncology (NASDAQ:ZIOP) opened at $3.83 on Friday. It has underperformed by 14.95% the S&P500. Menta Ltd Liability reported 24,476 shares. Geode Capital Management LLC now owns 1,160,653 shares of the biotechnology company's stock worth $4,805,000 after purchasing an additional 22,575 shares during the period. Its revenue stood at 7.90% a year on average in the period of last five years. Closing price generally refers to the last price at which a stock trades during a regular trading session. About 27,733 shares traded. Monsanto Company (NYSE:MON) has risen 15.46% since March 7, 2017 and is uptrending. It has outperformed by 58.38% the S&P500. Therefore 25% are positive. Finally, Northern Trust Corp grew its position in shares of ZIOPHARM Oncology by 10.1% during the second quarter. Most of the active traders and investors are keen to find ways to compare the value of stocks. The company was maintained on Thursday, December 14 by H.C. Wainwright. Finally, Deutsche Bank AG grew its position in ZIOPHARM Oncology by 141.1% in the 4th quarter. (NASDAQ:ZIOP) on Thursday, December 14 with "Buy" rating. (NASDAQ:ZIOP) earned "Buy" rating by H.C. Wainwright on Monday, March 5.

Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $7.25 on the stock, this valuation is based on 2 number of opinions. (NASDAQ:ZIOP) has "Market Perform" rating given on Wednesday, August 10 by Wells Fargo. The firm has "Market Perform" rating given on Thursday, June 2 by Raymond James. Wells Fargo initiated the shares of ZIOP in report on Friday, December 4 with "Underperform" rating.

Shares of Ziopharm Oncology In (NASDAQ:ZIOP) now have an Average Brokerage Recommendation of 2.2, number of Recs in ABR is 5 while industry rank of the company by ABR is 195 out of 265. The company have shares float of 139.17 million. Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Pinnacle Associates Ltd increased Delphi Automotive Plc (NYSE:DLPH) stake by 9,340 shares to 61,215 valued at $6.02 million in 2017Q3.

Earnings per share is the portion of a company's profit allocated to each outstanding share of common stock. Vanguard Index Fds (VB) was raised too.

Investors sentiment decreased to 0.81 in 2017 Q3. Its up 0.17, from 1.1 in 2017Q2. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 59 are held by Hanson Mcclain Incorporated.

Ever wonder how investors predict positive share price momentum? 0 analysts call it Underweight, while 2 think it is Overweight. $966,720 worth of Monsanto Company (NYSE:MON) shares were sold by MIZELL STEVEN. Zweig owns 75,000 shares. Sequoia Financial Advsr Limited Com invested in 0.48% or 33,480 shares. (NYSE:CMI) for 1,700 shares. Old Mutual Customised Solutions (Proprietary) has invested 0.13% of its portfolio in Monsanto Company (NYSE:MON). (NYSE:CMI) for 1,281 shares. The stock of Regis Corporation (NYSE:RGS) has "Buy" rating given on Wednesday, November 1 by Jefferies.

Beta measures volatility or systematic risk, of a stock or a portfolio in comparison to the market as a whole. The score helps determine if a company's stock is valuable or not. RBC Capital Markets maintained Cummins Inc. The stock of Cummins Inc. (NASDAQ:ZIOP), Stochastic %D value stayed at 72.69% for the last 9 days. (NYSE:CMI) to report earnings on May, 1. Now have a look at past performance (weekly performance to year to date performance) how ZIOPHARM Oncology, Inc. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.13).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.